- Conditions
- Urinary Tract Infections
- Interventions
- RO7079901, Meropenem
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- La Mesa, California • Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 36
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Urinary Tract Infections, Bladder, Neurogenic
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Complicated Urinary Tract Infection
- Interventions
- CXA-101, Ceftazidime
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Orlando, Florida • Decatur, Georgia + 4 more
- Conditions
- Complicated Urinary Tract Infection Including Acute Pyelonephritis
- Interventions
- Combination of Imipenem/Cilastatin and XNW4107, Meropenem
- Drug
- Lead sponsor
- Evopoint Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Infections, Urinary Tract
- Interventions
- GSK2251052, imipenem-cilastatin, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Council Bluffs, Iowa • Topeka, Kansas + 1 more
- Conditions
- Acute Pyelonephritis, Complicated Urinary Tract Infection
- Interventions
- Meropenem-Vaborbactam, Antibiotics
- Drug
- Lead sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
- Industry
- Eligibility
- 3 Months to 11 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Orange, California • Omaha, Nebraska + 1 more
- Conditions
- Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
- Interventions
- ZTI-01, Piperacillin-tazobactam
- Drug
- Lead sponsor
- Nabriva Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more
- Conditions
- Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Abdominal Infection
- Interventions
- Vabomere, Best Available Therapy
- Drug
- Lead sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 20
- States / cities
- Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
- Conditions
- Complicated Urinary Tract Infection
- Interventions
- NXL104/ceftazidime, Imipenem/Cilastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 38 more
- Conditions
- Urinary Tract Infections, Complicated Urinary Tract Infection
- Interventions
- Not listed
- Lead sponsor
- Pathnostics
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 7,921 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), Complicated Urinary Tract Infection (cUTI), Ventilator Associated Bacterial Pneumonia (VABP)
- Interventions
- Cefiderocol, Standard of Care
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Fort Worth, Texas
- Conditions
- cUTI
- Interventions
- Eravacycline, Levofloxacin
- Drug
- Lead sponsor
- Tetraphase Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 908 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- San Diego, California • Torrance, California • Tampa, Florida + 3 more
- Conditions
- Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
- Interventions
- Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 641 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania
- Conditions
- Complicated Urinary Tract Infections
- Interventions
- LYS228, Standard of care therapy
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Newark, New Jersey • Seattle, Washington
- Conditions
- Urinary Tract Infection
- Interventions
- Fosfomycin tromethamine, Levofloxacin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 12
- States / cities
- Sylmar, California • Torrance, California • Decatur, Georgia + 9 more
- Conditions
- Complicated Urinary Tract Infections
- Interventions
- Eravacycline, Ertapenem, Placebo, Levofloxacin
- Drug
- Lead sponsor
- Tetraphase Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Fullerton, California • Los Angeles, California • Torrance, California + 7 more
- Conditions
- Complicated Urinary Tract Infection, Acute Pyelonephritis
- Interventions
- TBPM-PI-HBr, Ertapenem, Dummy Infusion, Dummy tablets
- Drug
- Lead sponsor
- Spero Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- La Mesa, California • Miami, Florida
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
- Interventions
- Cefiderocol, Best Available Therapy
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
- Conditions
- Urinary Tract Infections
- Interventions
- Ceftaroline fosamil and NXL104 (q8h), Ceftaroline fosamil and NXL104 (q12h), Doripenem, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- La Mesa, California • San Diego, California • Pensacola, Florida + 2 more
- Conditions
- Complicated Urinary Tract Infections or Pyelonephritis
- Interventions
- Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Oakland, California • Orange, California + 8 more
- Conditions
- Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI), Urinary Tract Infection (Diagnosis)
- Interventions
- Treatment guided by the PCR results, Treatment guided by the C&S results
- Diagnostic Test
- Lead sponsor
- Doc Lab Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 773 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- San Jose, California • Albany, Georgia • Evans, Georgia + 3 more
- Conditions
- Urinary Tract Infection Complicated, Acute Pyelonephritis
- Interventions
- Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin, Saline
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 8
- States / cities
- Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more
- Conditions
- Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
- Interventions
- Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Sylmar, California • Royal Oak, Michigan • Lima, Ohio
- Conditions
- Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
- Interventions
- Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Shreveport, Louisiana • Lima, Ohio